metapristone profile

metapristone: a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10070462
CHEMBL ID	1608
SCHEMBL ID	4020579
MeSH ID	M000599185

Synonyms (32)

Synonym
ru 42633
desmethylmifepristone
CHEMBL1608 ,
SCHEMBL4020579
bdbm50292750
17beta-hydroxy-17alpha-propynyl-11beta-(4-n-methylaminophenyl)-estra-4,9-dien-3-one
17beta-hydroxy-11beta-[4-(methylamino)-phenyl]-17alpha-(1-propinyl)-estra-4,9-dien-3-one
104004-96-8
n-desmethyl-ru 486
estra-4,9-dien-3-one, 17-hydroxy-11-(4-(methylamino)phenyl)-17-(1-propynyl)-, (11beta,17beta)-
metapristone
k1p8ogj86j ,
unii-k1p8ogj86j
ru-42633
n-demethyl mifepristone
n-methylaminopristone
estra-4,9-dien-3-one, 17-hydroxy-11-(4-(methylamino)phenyl)-17-(1-propynyl)-, (11.beta.,17.beta.)-
estra-4,9-dien-3-one, 17-hydroxy-11-(4-(methylamino)phenyl)-17-(1-propyn-1-yl)-, (11.beta.,17.beta.)-
mifepristone, n-monodemethyl
AKOS025294003
n-desmethyl mifepristone
DTXSID60146216
(8s,11r,13s,14s,17s)-17-hydroxy-13-methyl-11-[4-(methylamino)phenyl]-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
J-001090
(11r,13s,14s,17s)-17-hydroxy-13-methyl-11-(4-(methylamino)phenyl)-17-(prop-1-ynyl)-6,7,8,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
Q27281827
(11beta,17beta)-17-hydroxy-11-[4-(methylamino)phenyl]-17-(1-propyn-1-yl)-estra-4,9-dien-3-one
EN300-6762714
(1s,3as,3bs,10r,11as)-1-hydroxy-11a-methyl-10-[4-(methylamino)phenyl]-1-(prop-1-yn-1-yl)-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
ru42633
(8s,11r,13s,14s,17s)-17-hydroxy-13-methyl-11-(4-(methylamino)phenyl)-17-(prop-1-ynyl)-6,7,8,11,12,13,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
Z3028399069

Research Excerpts

Treatment

Excerpt	Reference	Relevance
"Metapristone-treatment caused the cell arrest at the G0/G1 stage, and the inhibition of colony formation in B16F10 cells."	( Metapristone (RU486 derivative) inhibits cell proliferation and migration as melanoma metastatic chemopreventive agent. Chen, J; Jia, L; Liu, J; Liu, W; Wang, J; Zheng, N, 2017)	2.62

Pharmacokinetics

Excerpt	Reference	Relevance
" There was a wide variability (up to ten-fold) in the pharmacokinetic parameters within each dose group."	( Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Fotherby, K; He, CH; Shi, YE; Van Look, PF; Xu, JQ; Ye, ZH; Zhang, GQ, 1993)	0.29

Dosage Studied

Excerpt	Relevance	Reference
" They gave the same dosage of mifepristone to 12 similar women, but took fetal blood samples at 24 or 48 hours post treatment."	( Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy. Ferguson, J; Hill, NC; MacKenzie, IZ; Selinger, M, 1991)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Progesterone receptor	Homo sapiens (human)	IC50 (µMol)	0.0001	0.0000	0.5807	10.0000	AID345893; AID345895; AID461850
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
ovulation from ovarian follicle	Progesterone receptor	Homo sapiens (human)
glandular epithelial cell maturation	Progesterone receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Progesterone receptor	Homo sapiens (human)
signal transduction	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
cell-cell signaling	Progesterone receptor	Homo sapiens (human)
positive regulation of gene expression	Progesterone receptor	Homo sapiens (human)
negative regulation of gene expression	Progesterone receptor	Homo sapiens (human)
paracrine signaling	Progesterone receptor	Homo sapiens (human)
negative regulation of phosphorylation	Progesterone receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
lung alveolus development	Progesterone receptor	Homo sapiens (human)
regulation of epithelial cell proliferation	Progesterone receptor	Homo sapiens (human)
progesterone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
maintenance of protein location in nucleus	Progesterone receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Progesterone receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
transcription coactivator binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
DNA binding	Progesterone receptor	Homo sapiens (human)
nuclear steroid receptor activity	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor activity	Progesterone receptor	Homo sapiens (human)
steroid binding	Progesterone receptor	Homo sapiens (human)
protein binding	Progesterone receptor	Homo sapiens (human)
zinc ion binding	Progesterone receptor	Homo sapiens (human)
enzyme binding	Progesterone receptor	Homo sapiens (human)
identical protein binding	Progesterone receptor	Homo sapiens (human)
ATPase binding	Progesterone receptor	Homo sapiens (human)
estrogen response element binding	Progesterone receptor	Homo sapiens (human)
nuclear receptor activity	Progesterone receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Progesterone receptor	Homo sapiens (human)
mitochondrial outer membrane	Progesterone receptor	Homo sapiens (human)
cytosol	Progesterone receptor	Homo sapiens (human)
chromatin	Progesterone receptor	Homo sapiens (human)
nucleus	Progesterone receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID461850	Antiprogestagenic activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells.
AID1381653	Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
AID461851	Antiprogestagenic activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity relative to mifepristone	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Synthesis, in vitro progesterone receptors affinity of gadolinium containing mifepristone conjugates and estimation of binding sites in human breast cancer cells.
AID1381652	Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
AID345895	Antagonist activity at progesterone receptor in human T47D-C124 cells transfected with luciferase gene linked to MMTV promoter assessed as inhibition of progesterone-induced luciferase transactivation activity after 24 hrs	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Syntheses and antigestagenic activity of mifepristone derivatives.
AID345894	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity after 48 hrs relative to mifepristone	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Syntheses and antigestagenic activity of mifepristone derivatives.
AID345893	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity after 48 hrs	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Syntheses and antigestagenic activity of mifepristone derivatives.
AID345896	Antagonist activity at progesterone receptor in human T47D-C124 cells transfected with luciferase gene linked to MMTV promoter assessed as inhibition of progesterone-induced luciferase transactivation activity after 24 hrs relative to mifepristone	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	Syntheses and antigestagenic activity of mifepristone derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (6.25)	18.7374
1990's	2 (12.50)	18.2507
2000's	1 (6.25)	29.6817
2010's	12 (75.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (6.25%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	5.59	16	1	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
sorafenib [no description available]	7.21	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
gw 4869 GW 4869: inhibits neutral sphingomyelinase; structure in first source	2.17	1	0

Condition	Relationship Strength	Studies	Trials
Breast Cancer [description not available]	2.46	2	0
Hormone-Dependent Neoplasms [description not available]	2.05	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.46	2	0
Experimental Neoplasms [description not available]	2.17	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.77	2	1
Malignant Melanoma [description not available]	2.15	1	0
Metastase [description not available]	3.04	4	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	7.15	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.04	4	0
Carcinoma, Non-Small Cell Lung [description not available]	2.15	1	0
Cancer of Lung [description not available]	2.54	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.15	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.54	2	0
Cancer of Cervix [description not available]	2.17	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.17	1	0
Hepatocellular Carcinoma [description not available]	7.21	1	0
Cancer of Liver [description not available]	2.21	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.21	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.21	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.13	1	0
B16 Melanoma [description not available]	2.13	1	0
Acute Liver Injury, Drug-Induced [description not available]	2.13	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.13	1	0
Invasiveness, Neoplasm [description not available]	2.54	2	0
Epithelial Ovarian Cancer [description not available]	2.15	1	0
Epithelial Neoplasms [description not available]	2.15	1	0
Cancer of Ovary [description not available]	2.15	1	0
Peritoneal Carcinomatosis [description not available]	2.15	1	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	2.15	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.15	1	0
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	2.15	1	0

metapristone

Description

Cross-References

Synonyms (32)

Research Excerpts

Treatment

Pharmacokinetics

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Biological Processes (18)

Molecular Functions (15)

Ceullar Components (6)

Bioassays (8)

Research

Studies (16)

Market Indicators

Research Demand Index: 113.03

Study Types

metapristone

Description

Cross-References

Synonyms (32)

Research Excerpts

Treatment

Pharmacokinetics

Dosage Studied

Protein Targets (1)

Inhibition Measurements

Biological Processes (18)

Molecular Functions (15)

Ceullar Components (6)

Bioassays (8)

Research

Studies (16)

Market Indicators

Research Demand Index: 113.03

Study Types

Related Drugs (3)

Related Conditions (31)